Fertility Glossary
Every fertility term explained in simple, clear language. From treatments and tests to hormones and conditions — understand your fertility journey with confidence.
📂 Browse by Category
Core Medical Terms
Fertility
Fertility is the natural capacity to conceive a pregnancy and produce offspring. It refers to the overall reproductive potential of an individual or couple, and is influenced by factors such as age, hormonal health, anatomy, sperm quality, and general medical well-being. Fertility is not binary — it exists on a spectrum, from high fecundity (easy conception) to subfertility (delayed conception) to infertility (inability to conceive without intervention). In clinical practice, fertility is assessed through a combination of hormonal tests, imaging, and semen analysis to guide treatment decisions.
Fecundity
Fecundity is the biological ability to reproduce, often measured as the probability of achieving a conception per menstrual cycle, also referred to as fecundability. A healthy couple under 35 with no known fertility issues has a monthly fecundability of approximately 20–25%. Fecundity declines naturally with age, particularly after 35 in women, and can be reduced by conditions such as PCOS, endometriosis, low sperm count, or unexplained infertility. It is a key epidemiological concept used in fertility research and clinical population studies to measure and compare reproductive capacity across groups.
Subfertility
Subfertility refers to reduced fertility with a prolonged time to conception, but without a complete inability to conceive naturally. A couple is typically described as subfertile if they have been trying to conceive for 12 months or more (or 6 months if the woman is over 35) without success, but where the potential for natural pregnancy still exists. Unlike absolute infertility, subfertility implies that conception is possible but takes longer than average. It covers a broad spectrum of mild reproductive challenges — including mild ovulatory irregularities, borderline sperm parameters, or age-related decline — and is the most common reason couples present to fertility specialists.
Infertility
Infertility is defined as the failure to achieve a clinical pregnancy after 12 months of regular, unprotected sexual intercourse — or after 6 months in women aged 35 or older, or in the presence of known risk factors such as irregular ovulation, prior pelvic infection, or significant male factor issues. Infertility affects approximately 1 in 7 couples globally and 1 in 6 in India. It can be primary (never achieved a prior pregnancy) or secondary (inability to conceive after a previous pregnancy). Causes are distributed broadly: approximately one-third are attributed to female factors, one-third to male factors, and one-third to combined or unexplained causes. A structured fertility workup and staged treatment plan — from ovulation induction to IUI to IVF — can help most couples achieve pregnancy.
Primary Infertility
Primary infertility is defined as infertility in a person or couple who has never previously achieved a clinical pregnancy. It is distinguished from secondary infertility, where at least one prior pregnancy (regardless of outcome) has occurred. Primary infertility accounts for approximately 60–70% of infertility presentations in India. It can result from a wide range of causes — including ovulatory disorders (such as PCOS), tubal blockage, uterine abnormalities, male factor infertility, or unexplained causes — and requires a comprehensive fertility evaluation covering both partners. Treatment follows a stepwise approach based on findings, beginning with the least invasive options and escalating to IVF or ICSI when needed.
Secondary Infertility
Secondary infertility is defined as the inability to achieve a clinical pregnancy in a person or couple who has previously conceived — regardless of whether that prior pregnancy resulted in a live birth, miscarriage, or termination. It is often unexpected and can be emotionally difficult, as prior pregnancy gives a false sense of reassurance about fertility. Secondary infertility may arise from new or progressive causes including uterine adhesions (Asherman's syndrome), age-related decline in egg quality, acquired endometriosis, hormonal changes, or deterioration in sperm parameters over time. A structured fertility evaluation covering both partners is essential, as the underlying cause may be different from what caused the previous pregnancy.
Fecundability
Fecundability is the probability of achieving a clinical pregnancy within a single menstrual cycle, assuming regular unprotected intercourse throughout that cycle. It is the cycle-specific measure of fertility and is the key metric used in epidemiological fertility research. For a healthy couple under 35, monthly fecundability is approximately 20–25%. It declines with advancing age — particularly after 35 in women — and is reduced by conditions affecting ovulation, sperm quality, fallopian tube function, or uterine receptivity. Clinicians and researchers use fecundability to model time-to-pregnancy distributions and to quantify the impact of fertility-affecting conditions or treatments.
Reproductive Endocrinology
Reproductive endocrinology is a medical subspecialty focused on the hormonal regulation of reproduction, the diagnosis and management of fertility disorders, and the application of assisted reproductive technologies. Reproductive endocrinologists (REs) are OB/GYN-trained physicians who complete additional specialised fellowship training in fertility medicine. They manage a broad range of conditions including ovulatory disorders, PCOS, premature ovarian insufficiency, recurrent pregnancy loss, male factor infertility, and unexplained infertility. In India, the specialty is growing rapidly with dedicated fertility clinics and specialist centres in most major cities.
Gamete
A gamete is a mature reproductive cell that contains a haploid set of chromosomes (half the normal diploid number), produced through the process of meiosis. In human reproduction, the two types of gametes are the oocyte (female egg cell) and the sperm (male reproductive cell). Fertilisation occurs when a sperm fuses with an oocyte, combining their chromosomes to form a diploid zygote with a full complement of 46 chromosomes. The quality, quantity, and integrity of gametes are central concerns in fertility medicine — poor egg or sperm quality is a leading cause of failed fertilisation, abnormal embryo development, and recurrent pregnancy loss.
Oocyte
An oocyte is the female reproductive cell — the egg — produced by the ovaries. At birth, a female has a finite number of immature oocytes (approximately 1–2 million), which decline over time. By puberty, approximately 300,000–400,000 remain. Only a small fraction are ever released through ovulation over a woman's reproductive life. In fertility treatment, oocyte quality is as important as quantity — egg quality declines with age, particularly after 35, increasing the risk of chromosomal abnormalities. During IVF, oocytes are retrieved from ovarian follicles after hormonal stimulation and assessed for maturity before fertilisation.
Egg
Egg is the lay term for the oocyte — the female reproductive cell released from the ovary during ovulation. In everyday fertility conversations and patient education, "egg" is used interchangeably with oocyte. Egg quality refers to the likelihood that an oocyte is chromosomally normal and capable of being fertilised and developing into a healthy embryo. Egg quantity refers to ovarian reserve — the number of eggs remaining. Both quality and quantity decline with age. In IVF, the goal of ovarian stimulation is to recruit and mature as many high-quality eggs as possible for retrieval and fertilisation.
Sperm
Sperm (spermatozoa) are the male reproductive cells responsible for fertilising the female oocyte. They are produced continuously in the testes through a process called spermatogenesis, which takes approximately 72–74 days. A healthy sperm has an oval head (containing genetic material), a midpiece (packed with mitochondria for energy), and a flagellum (tail) for motility. Key parameters assessed in semen analysis include count (concentration), motility (forward movement), morphology (shape), and DNA integrity. Sperm quality is affected by age, lifestyle factors (smoking, alcohol, heat exposure), hormonal imbalances, infections, and genetic conditions. Even with very poor sperm quality, ICSI can achieve fertilisation using a single viable sperm.
Embryo
An embryo is the developing human organism from the moment of fertilisation through approximately the eighth week of gestation. In reproductive medicine, the term is used from day 1 (zygote) through the blastocyst stage (day 5–7) and beyond. Embryo quality is one of the most critical factors in IVF success — it is assessed using grading systems that evaluate cell number, symmetry, fragmentation, and (at the blastocyst stage) inner cell mass and trophectoderm quality. High-quality embryos are more likely to implant successfully. Embryos that are not transferred immediately can be cryopreserved for use in future frozen embryo transfer (FET) cycles.
Ovarian Reserve
Ovarian reserve refers to the quantity and functional potential of remaining oocytes in the ovaries. It reflects the size of a woman's remaining egg pool and is the primary predictor of her reproductive lifespan. Ovarian reserve is assessed clinically using AMH blood test, antral follicle count (AFC) on transvaginal ultrasound, and Day 3 FSH — with AMH being the most reliable single marker. Reserve declines naturally with age, and can be prematurely reduced by ovarian surgery, endometriosis, chemotherapy, or genetic factors. Low ovarian reserve does not preclude pregnancy but may require modified IVF protocols or donor eggs.
Egg Reserve
Egg reserve is the lay term for ovarian reserve — referring to the remaining pool of eggs available in a woman's ovaries. It is assessed through AMH testing and antral follicle count. A woman's egg reserve begins declining at birth and reduces more steeply after age 35. Low egg reserve affects the number of eggs available for IVF stimulation but does not necessarily indicate poor egg quality — particularly in younger women.
Egg Quality
Egg quality refers to the developmental competence and chromosomal normality of oocytes — specifically, the likelihood that an egg can be fertilised and develop into a chromosomally normal embryo capable of implantation. Egg quality declines significantly with age: after 38, the majority of oocytes carry chromosomal abnormalities (aneuploidy). Unlike egg reserve (quantity), egg quality cannot be directly measured before retrieval. In IVF, it is inferred from embryo development patterns, blastocyst formation rate, and PGT-A results. Poor egg quality is the leading cause of age-related IVF failure and miscarriage.
Semen
Semen is the ejaculated fluid produced by the male reproductive system, containing sperm cells and secretions from the seminal vesicles, prostate gland, and bulbourethral glands. The sperm-rich fraction makes up only a small proportion of semen volume. Semen provides nutrients, buffers, and an environment that supports sperm motility and viability. Semen analysis evaluates key parameters including volume, pH, sperm concentration, total count, motility, morphology, and vitality to assess male fertility potential.
Zona Pellucida
The zona pellucida is a glycoprotein shell surrounding the oocyte and early embryo, approximately 15–20 µm thick. It serves multiple reproductive functions: it acts as a species-specific sperm receptor (via ZP2 and ZP3 proteins), triggers the acrosome reaction during fertilisation, prevents polyspermy through the zona reaction, and protects the developing embryo during its journey through the fallopian tube. In IVF, the zona may be artificially thinned (assisted hatching) to facilitate blastocyst hatching and improve implantation in selected patients. In ICSI, the zona pellucida is pierced mechanically by the injection needle.
Oxidative Stress
Oxidative stress occurs when the production of reactive oxygen species (ROS) — unstable molecules including hydrogen peroxide, superoxide, and hydroxyl radicals — exceeds the body's antioxidant defence capacity. In reproductive medicine, oxidative stress damages sperm DNA (raising DNA fragmentation index), impairs oocyte mitochondrial function, disrupts embryo development, and compromises endometrial receptivity. It is elevated by varicocele, infection, smoking, obesity, advanced age, and environmental toxins. Antioxidant supplementation is the primary strategy for reducing reproductive oxidative stress.
Maternal Age
Maternal age is the age of the female reproductive partner at conception or delivery. It is the single most important determinant of female fertility, egg quality, chromosomal risk, and ART success. Fertility declines from 32, steeply from 37, and markedly after 40. Chromosomal aneuploidy in eggs rises from approximately 20% at age 35 to over 60% at 40 and over 80% at 43 — explaining the parallel rise in miscarriage rates and fall in IVF success. Advanced maternal age (AMA) is clinically defined as ≥35 at delivery in obstetrics and ≥38–40 in fertility medicine.
Paternal Age
Paternal age is the age of the male partner at conception. Unlike in women, sperm production is continuous throughout life — but sperm quality declines gradually from approximately age 40–45. Advanced paternal age (>40 years) is associated with increased sperm DNA fragmentation, reduced sperm motility and morphology, longer time to pregnancy, higher miscarriage rates, and modestly increased risk of certain de novo genetic conditions in offspring (autism spectrum disorder, schizophrenia, achondroplasia). The effect is less dramatic than maternal age but clinically relevant when paternal age exceeds 45–50.
Testicular Sperm
Testicular sperm are sperm cells retrieved directly from testicular tissue via surgical biopsy (TESE) or microsurgical extraction (Micro-TESE), rather than from the ejaculate. They are immature, typically non-motile, and used exclusively with ICSI. Testicular sperm have lower DNA fragmentation than ejaculated sperm in men with elevated sperm DNA index — making them the preferred source for men with recurrent IVF failure linked to sperm DNA damage.
Epididymis
The epididymis is the tightly coiled duct on the posterior surface of each testis where sperm undergo final maturation and gain fertilising capacity. Approximately 6 metres long when uncoiled, it stores up to 200–500 million sperm, primarily in the cauda (tail). Epididymal obstruction — from vasectomy, infection, or CBAVD — causes obstructive azoospermia. Sperm retrieved from the epididymis via PESA or MESA achieve 70–80% fertilisation rates with ICSI.
What is a Blastocyst
A blastocyst is a Day 5–7 embryo containing 100–200+ cells, characterised by a fluid-filled blastocoel cavity, an inner cell mass (ICM — becomes the foetus), and a trophectoderm (TE — becomes the placenta). It is the preferred embryo stage for IVF transfer and PGT-A genetic testing. Implantation rate per blastocyst transfer: 50–65% — significantly higher than Day 3 (cleavage stage) transfer at 30–40%.
Biological Processes
Conception
Conception is the process by which pregnancy begins, encompassing both the fertilisation of an oocyte (egg) by a sperm cell to form a zygote, and the subsequent successful implantation of the developing embryo into the uterine lining. In clinical terms, a pregnancy is not considered established until implantation occurs — fertilisation alone is not sufficient. Conception can occur naturally through timed intercourse, or be assisted through fertility treatments such as IUI or IVF. The window for natural conception in each cycle is narrow — typically 5–6 days ending at ovulation — and overall monthly probability of conception in a healthy couple under 35 is approximately 20–25%.
Fertilization
Fertilization is the biological process in which a single sperm cell penetrates and fuses with a mature oocyte (egg) to form a diploid zygote — the earliest form of a new organism. This occurs in the ampullary region of the fallopian tube under natural conditions. The process involves a series of molecular events: sperm capacitation (activation in the female reproductive tract), the acrosome reaction (release of enzymes that allow sperm to penetrate the egg's outer layers), and fusion of the sperm and egg cell membranes. Once fertilized, the zygote begins dividing and travels toward the uterus for implantation. In ART (IVF/ICSI), fertilization occurs in a laboratory setting under controlled conditions.
Menstrual Cycle
The menstrual cycle is a recurring hormonal cycle that prepares the female reproductive system for possible pregnancy each month. It is regulated by coordinated rises and falls in FSH, LH, estrogen, and progesterone. A typical cycle lasts 21–35 days and is divided into distinct phases: the follicular phase (follicle development), ovulation (egg release), and the luteal phase (preparation for implantation). Day 1 of the cycle is defined as the first day of full menstrual bleeding. Understanding the menstrual cycle is fundamental to fertility treatment — it determines when to perform tests, administer medications, and time intercourse or procedures for optimal results.
Follicular Phase
The follicular phase is the first half of the menstrual cycle, beginning on Day 1 (the onset of menstruation) and ending at ovulation. During this phase, rising FSH levels stimulate several ovarian follicles to grow. One follicle — the dominant follicle — emerges and grows to approximately 18–22 mm, producing increasing amounts of estradiol. This estrogen rise thickens the uterine lining and, when it peaks, triggers a surge in LH that leads to ovulation. In IVF, the follicular phase is closely monitored with serial ultrasounds and blood tests to assess follicle growth and guide medication dosing.
Ovulation
Ovulation is the release of a mature oocyte (egg) from a dominant ovarian follicle, triggered by a sharp surge in LH (luteinising hormone) approximately 24–36 hours before egg release. It typically occurs around the middle of the menstrual cycle — Day 14 in a standard 28-day cycle — though timing varies. The released egg survives for only 12–24 hours, during which fertilisation must occur. Sperm can survive in the female reproductive tract for up to 5 days, making the 5–6 days leading up to and including ovulation the fertile window. Accurate detection of ovulation — through LH tests, ultrasound monitoring, or basal body temperature tracking — is central to fertility treatment planning.
Luteal Phase
The luteal phase is the second half of the menstrual cycle, beginning at ovulation and ending at the onset of the next menstruation (or continuing if pregnancy occurs). After the egg is released, the ruptured follicle transforms into the corpus luteum, which secretes progesterone. Progesterone prepares the endometrium (uterine lining) for embryo implantation, making it thicker and more receptive. If implantation does not occur, the corpus luteum degenerates, progesterone falls, and menstruation begins. In IVF cycles, progesterone supplementation is given during the luteal phase to support implantation. A luteal phase shorter than 10 days may indicate luteal phase deficiency.
Fertile Window
The fertile window is the approximately 5–6 day period in each menstrual cycle during which sexual intercourse can result in pregnancy. It spans the 5 days before ovulation and the day of ovulation itself — reflecting the fact that sperm can survive in the female reproductive tract for up to 5 days, while the released egg is viable for only 12–24 hours. Accurately identifying the fertile window is the foundation of timed intercourse and natural conception efforts. It can be tracked using ovulation predictor kits (LH tests), basal body temperature charting, cervical mucus observation, or ultrasound monitoring. For couples TTC, timing intercourse during the fertile window is the single most impactful behavioural factor.
Cervical Mucus
Cervical mucus is a secretion produced by glands in the cervix, whose quantity, consistency, and quality change predictably across the menstrual cycle in response to hormonal fluctuations. During the follicular phase, as estrogen rises, mucus becomes increasingly abundant, clear, and stretchy — a characteristic known as "egg white" cervical mucus (EWCM) — which is most conducive to sperm transport and survival. After ovulation, rising progesterone causes mucus to become thick, cloudy, and hostile to sperm. Monitoring cervical mucus is a key component of fertility awareness methods and natural cycle tracking, helping women identify their fertile window without technological aids.
LH Surge
The LH surge is a sharp, rapid rise in luteinising hormone (LH) secreted by the pituitary gland, occurring approximately 24–48 hours before ovulation. It is triggered by peak estradiol levels from the dominant follicle and acts as the physiological signal that causes the dominant follicle to rupture and release the mature oocyte. In natural cycle tracking, the LH surge is detected using urine-based ovulation predictor kits (OPKs), which change colour when LH exceeds a threshold concentration. In stimulated IVF and IUI cycles, the LH surge is often controlled or replaced pharmacologically using a trigger injection (hCG or GnRH agonist) to allow precise timing of egg retrieval or insemination.
Zygote
A zygote is the single-cell organism formed immediately after fertilisation — when a sperm cell fuses with an oocyte, combining their genetic material into a diploid cell with 46 chromosomes. The zygote is the earliest stage of embryonic development. Within hours of fertilisation, the zygote begins dividing through a process called cleavage, progressing from 2 cells to 4, 8, and 16 cells (the morula) over the following 3 days, before developing into a blastocyst by day 5–6. In IVF, the fertilisation of retrieved eggs is confirmed by identifying the characteristic two pronuclei (2PN) of the newly formed zygote under a microscope, approximately 16–18 hours after insemination or ICSI.
Blastocyst
A blastocyst is a day 5 to 7 embryo that has developed a fluid-filled central cavity (the blastocoele), an inner cell mass (ICM, which becomes the fetus), and an outer layer of cells called the trophectoderm (which becomes the placenta). Reaching the blastocyst stage is a key milestone in embryo development, as it demonstrates the embryo's capacity to survive and self-organise. In IVF, blastocyst-stage transfer is increasingly preferred over day 3 (cleavage-stage) transfer because it allows for better embryo selection — only the strongest embryos reach day 5 — leading to higher implantation rates per transfer. Blastocysts can also be biopsied for preimplantation genetic testing (PGT) before transfer.
Capacitation
Capacitation is the process by which sperm undergo physiological and biochemical changes — primarily in the female reproductive tract — that confer the ability to fertilise an oocyte. These changes include alterations in membrane fluidity, increased intracellular calcium, hyperactivation of sperm motility, and priming for the acrosome reaction. Capacitation takes approximately 5–7 hours in the female tract. In IVF and IUI laboratories, sperm are processed (washed, density gradient centrifugation) to mimic and accelerate capacitation in vitro, selecting the most capable sperm for insemination or ICSI.
Acrosome Reaction
The acrosome reaction is the release of hydrolytic enzymes from the acrosome — a cap-like vesicle on the sperm head — that enables the sperm to penetrate the zona pellucida (outer coat) of the oocyte and achieve fertilisation. It is triggered when a capacitated sperm binds to the zona pellucida via ZP3 glycoprotein receptors, causing calcium influx and exocytosis of the acrosomal contents. Enzymes released — including acrosin and hyaluronidase — digest the zona pellucida, enabling sperm penetration. In ICSI, the acrosome reaction is bypassed because the sperm is injected directly into the oocyte.
Patient Journey
Time to Pregnancy (TTP)
Time to Pregnancy (TTP) is the duration — measured in menstrual cycles or months — from when a couple begins actively trying to conceive until a clinical pregnancy is achieved. TTP is used as a key epidemiological measure of a population's fertility and as a clinical indicator of subfertility. A TTP of 12 months or longer (or 6 months for women over 35) in couples having regular unprotected intercourse meets the clinical definition for infertility investigation. TTP is influenced by age, cycle regularity, frequency of intercourse, sperm quality, and underlying reproductive health conditions. Tracking TTP helps clinicians decide when to initiate a fertility workup and how urgently to escalate treatment.
Trying to Conceive (TTC)
Trying to Conceive (TTC) is a widely used lay term describing the active effort by an individual or couple to achieve pregnancy through timed intercourse, ovulation tracking, or fertility treatment. The TTC journey typically begins with lifestyle optimisation and cycle awareness — including tracking basal body temperature, using ovulation predictor kits, and identifying the fertile window — and may escalate to clinical evaluation and assisted reproductive treatment if conception does not occur within a defined timeframe. The TTC experience encompasses significant emotional, physical, and relational dimensions, and many patients benefit from both medical and psychological support throughout the process.
REI Specialist (Reproductive Endocrinologist)
An REI specialist (Reproductive Endocrinologist and Infertility specialist) is a physician with advanced subspecialty training in the diagnosis and treatment of hormonal and fertility disorders. In India, fertility specialists are typically gynaecologists with additional training in reproductive medicine and ART. They provide comprehensive fertility evaluations covering both partners, manage conditions such as PCOS, endometriosis, recurrent miscarriage, and male factor infertility, and oversee assisted reproductive procedures including IUI, IVF, and ICSI. Choosing an experienced REI specialist at an accredited fertility centre is one of the most important decisions in a patient's fertility journey.
Fertility Clinic
A fertility clinic is a specialised medical centre that evaluates and treats infertility and reproductive disorders in both men and women. It is staffed by reproductive endocrinologists, gynaecologists, embryologists, andrologists, counsellors, and nursing staff, and is equipped with an IVF laboratory, diagnostic ultrasound, semen analysis facilities, and cryostorage for embryos and gametes. Fertility clinics in India range from standalone specialist centres to hospital-based units, and vary significantly in terms of success rates, infrastructure, technology, and cost. When choosing a fertility clinic, patients should evaluate accreditation status, laboratory standards, clinical experience, transparent success rate reporting, and emotional support offerings.
Preconception Care
Preconception care refers to the medical evaluation, health optimisation, and lifestyle modifications undertaken before attempting conception, with the goal of improving both fertility and maternal-fetal outcomes. It typically includes a full reproductive health assessment, nutritional review (including folic acid and vitamin D supplementation), vaccination review, management of chronic conditions (such as thyroid disorders, diabetes, or PCOS), screening for infections, review of current medications for teratogenicity, and counselling on weight, exercise, alcohol, and smoking. Preconception care is recommended for all couples considering pregnancy, and is especially important for those with known fertility challenges, prior pregnancy complications, or chronic medical conditions.
Cycle Day 1 (CD1)
Cycle Day 1 (CD1) is defined as the first day of full menstrual bleeding — not spotting — and marks the official beginning of a new menstrual cycle. It is a critical reference point in fertility treatment, as all cycle-based testing and medication protocols are timed from CD1. Baseline blood tests (FSH, LH, estradiol, AMH) and baseline ultrasound (antral follicle count) are typically scheduled for CD2 or CD3. Ovarian stimulation injections in IVF cycles are usually started between CD2 and CD5. Accurate identification of CD1 is essential for synchronising the patient's treatment protocol with their natural cycle.
Cycle Monitoring
Cycle monitoring is the planned combination of blood tests and ultrasound scans performed across a fertility treatment cycle to track follicle development, hormone levels, and endometrial response. It enables clinicians to adjust medication dosing, confirm ovulation, time insemination or egg retrieval, and assess treatment response. A standard IVF monitoring cycle includes baseline scan (Day 2–3), stimulation scans every 1–3 days, serial estradiol and progesterone measurements, and trigger timing assessment. Monitoring ensures both safety (preventing OHSS) and optimal treatment outcomes.
Cycle Start
Cycle start is the formal initiation point of a fertility treatment cycle — defined as the day a patient contacts the clinic on the first day of menstruation (Cycle Day 1) to confirm the beginning of a new IVF, IUI, or ovulation induction cycle. It is not merely a calendar date. It triggers the scheduling of all baseline investigations (Day 2–3 blood tests and ultrasound), the commencement of stimulation medications, and activates the clinical coordination team. In IVF, the cycle start sets the operational clock for the entire protocol — typically spanning 10–14 days of stimulation. Missing or misidentifying the cycle start desynchronises all subsequent monitoring and intervention timings.
Treatment Calendar
A treatment calendar is a personalised day-by-day schedule provided by the fertility clinic to the patient at the start of an IVF, IUI, or ovulation induction cycle. It maps every critical action: medication start dates, dosing instructions, monitoring scan appointments, trigger shot timing, egg retrieval or insemination date, embryo transfer window, and pregnancy test date. Each element is anchored to Cycle Day 1. The treatment calendar is the primary coordination tool that aligns the patient, clinical team, and IVF laboratory. Deviating from the calendar — missing a medication dose, attending a scan on the wrong day, or miscalculating the trigger window — can compromise the entire cycle.
Nurse Coordinator
A nurse coordinator (fertility nurse coordinator or IVF nurse) is a registered nurse with specialist training in reproductive medicine who acts as the primary point of contact for patients throughout a fertility treatment cycle. Their role spans clinical and administrative functions: conducting medication teaching sessions, scheduling monitoring appointments, interpreting early blood result trends for the physician, administering injections, liaising between the patient, REI physician, embryology laboratory, and pharmacy, and providing emotional support. In India, nurse coordinators are central to high-volume IVF centres, managing multiple simultaneous patient cycles. Their expertise directly impacts patient adherence, medication accuracy, and overall treatment experience.
Medication Teaching
Medication teaching is a structured educational session — conducted by a nurse coordinator or fertility nurse — in which patients are trained to correctly self-administer injectable fertility medications used in IVF and ovulation induction protocols. It covers the purpose and dose of each medication (typically FSH/hMG gonadotropins, GnRH antagonist, and the trigger injection), injection technique (subcutaneous or intramuscular), site rotation, needle disposal, storage requirements, and recognition of adverse effects. In India, injectable fertility medications are dispensed at cycle start and patients are expected to self-inject at home. Accurate medication teaching is the single most critical patient-preparation step in any stimulated cycle — dosing errors directly affect egg recruitment and cycle outcomes.
Infectious Disease Screening
Infectious disease screening is a mandatory pre-treatment blood test panel performed for both partners before starting any fertility treatment — including IVF, IUI, donor egg cycles, and surrogacy arrangements. It tests for HIV (types 1 and 2), Hepatitis B surface antigen (HBsAg), Hepatitis C antibody (HCV), and syphilis (RPR/VDRL). In India, infectious disease screening is required by the ICMR guidelines on ART and the ART (Regulation) Act 2021 before any treatment cycle and before gamete or embryo storage.
Support Groups
Fertility support groups are structured or informal peer communities where individuals and couples experiencing infertility, pregnancy loss, or treatment share experiences, coping strategies, and emotional support. They operate in-person (clinic-based or community) and online (forums, WhatsApp groups, social media communities). Research consistently shows participation reduces anxiety, depression, and social isolation during fertility treatment. They complement — but do not replace — professional counselling. In India, organisations such as Maitri and FOGSI-affiliated groups offer fertility-specific peer support.
Therapy (Fertility)
Fertility therapy refers to structured professional psychological support — provided by licensed psychologists, psychotherapists, or counsellors — to help individuals and couples cope with the emotional burden of infertility, treatment, pregnancy loss, and complex decisions (donor conception, surrogacy, stopping treatment). Evidence-based approaches used in fertility contexts include CBT (cognitive behavioural therapy), mindfulness-based therapy, and ACT (acceptance and commitment therapy). Infertility is associated with depression and anxiety rates comparable to chronic illness — professional therapy is a clinically recommended component of comprehensive fertility care.
Fertility Counseling
Fertility counselling is a specialised form of professional support addressing the emotional, relational, ethical, and decision-making dimensions of fertility care. It encompasses: emotional support through diagnosis and treatment, relationship counselling for couples experiencing strain from infertility, decision-counselling for third-party reproduction (donor eggs, donor sperm, surrogacy), grief counselling after pregnancy loss or failed treatment, and guidance when considering stopping treatment. In the UK and many European countries, fertility counselling is a mandatory component of licensed IVF treatment. In India, it is available at major fertility centres but inconsistently integrated.
Diagnostic Terms
Basal Body Temperature (BBT)
Basal body temperature (BBT) is the lowest resting body temperature of an individual, measured immediately upon waking — before any activity. It is used in fertility awareness methods to retrospectively identify ovulation: after ovulation, the rise in progesterone from the corpus luteum causes a sustained thermal shift of approximately 0.2–0.5°C above the pre-ovulatory baseline. This shift is detected by tracking BBT daily using a specialised basal thermometer (accurate to 0.1°C), and plotting readings on a chart. While BBT confirms that ovulation has already occurred, it does not predict when it will occur in future cycles — making it most useful for cycle awareness over time rather than real-time timed intercourse. It is often used alongside cervical mucus observation and OPK testing for a more complete fertility awareness picture.
Egg White Cervical Mucus (EWCM)
Egg white cervical mucus (EWCM) is a specific type of cervical secretion that appears in the days leading up to ovulation, characterised by its clear, slippery, and highly stretchy consistency — resembling raw egg white. It is produced in response to peak estrogen levels from the dominant follicle and represents the most fertile quality of cervical mucus in the cycle. EWCM is optimal for sperm survival and transport: its stretchiness (spinnbarkeit) allows sperm to pass through the cervix with minimal resistance and supports sperm motility toward the fallopian tubes. The presence of EWCM is one of the clearest physical signs of the fertile window and is widely used in fertility awareness methods and natural cycle tracking.
Ovulation Predictor Kit (OPK)
An ovulation predictor kit (OPK) is a home urine test that detects the LH surge preceding ovulation, providing advance warning of impending egg release. When the test line equals or exceeds the control line in intensity, it indicates a positive result — meaning ovulation is typically expected within 24–48 hours. OPKs are the most widely used and accessible method for identifying the fertile window and timing intercourse or IUI. Digital OPKs also measure estrogen levels to identify the wider fertile window (not just the LH peak). Limitations include false positives in women with PCOS (chronically elevated LH), and failure to detect ovulation if testing is mistimed. OPKs are a first-line tool for all couples attempting natural conception or undergoing timed intercourse cycles.
Sperm Count
Sperm count is the total number of sperm present in a complete ejaculate sample. It is calculated by multiplying sperm concentration (per mL) by the total semen volume. WHO 2021 reference: total sperm count ≥39 million per ejaculate. Low total sperm count is termed oligospermia. Sperm count is one of the three primary semen analysis parameters alongside motility and morphology and is a key determinant of the appropriate fertility treatment pathway.
Sperm Concentration
Sperm concentration is the number of sperm per millilitre of semen. WHO 2021 lower reference limit: ≥16 million/mL. It is distinct from total sperm count (which accounts for ejaculate volume). Sperm concentration below 16 million/mL is called oligospermia. It is used alongside total motile sperm count to guide treatment decisions — IUI typically requires >5 million motile sperm post-wash; ICSI can succeed with even a single viable sperm.
Motility
Sperm motility is the ability of sperm to move effectively. WHO 2021 reference: total motility ≥42%; progressive motility ≥30%. Sperm are classified as progressively motile (PR), non-progressively motile (NP), or immotile (IM). Progressive motility — forward-swimming sperm — is the most clinically relevant parameter. Low motility is termed asthenozoospermia. Motility is assessed alongside concentration and morphology to determine male fertility status and select appropriate treatment.
Progressive Motility
Progressive motility refers to forward-moving sperm — those swimming in a straight line or large curves. It is the most clinically relevant motility category for natural conception and IUI, as these are the sperm most capable of reaching and fertilising the oocyte. WHO 2021 lower reference: ≥30% progressive motility. Low progressive motility (asthenozoospermia) reduces natural conception probability and IUI success. ICSI bypasses the need for motility by directly injecting a single sperm into the egg.
Morphology
Sperm morphology is the assessment of sperm shape and structural appearance — evaluating the head, midpiece, and tail. It is assessed using strict Kruger criteria or standard WHO criteria. WHO 2021 reference: ≥4% normal forms (Kruger strict). Low morphology is termed teratozoospermia. Poor morphology does not prevent fertilisation through ICSI but is associated with lower natural conception and IVF success rates. Morphology is one component of the full semen analysis alongside count and motility.
Kruger Strict Morphology
Kruger strict morphology is a rigorous laboratory method for assessing sperm shape, in which sperm are classified as normal only if every structural element — head, acrosome, neck, midpiece, and tail — meets precise dimensional criteria. Introduced by Dr. Thinus Kruger, it is more stringent than standard WHO morphology criteria. Normal forms ≥4% is the reference threshold. Kruger strict morphology below 4% (teratozoospermia) is associated with reduced fertilisation in standard IVF, making ICSI the preferred technique.
Total Motile Sperm Count
Total motile sperm count (TMSC) is the total number of progressively moving sperm in an entire ejaculate sample — calculated as sperm concentration × volume × progressive motility fraction. It is the single most practically useful parameter for guiding treatment decisions. TMSC >20 million: natural conception or timed intercourse appropriate. TMSC 5–20 million: IUI indicated. TMSC <5 million: ICSI recommended. TMSC is a better predictor than concentration or motility alone.
Ejaculate Volume
Ejaculate volume is the total measured volume of semen produced in a single ejaculation. WHO 2021 reference: ≥1.4 mL. Low volume (hypospermia) may indicate retrograde ejaculation (sperm entering the bladder), ejaculatory duct obstruction, or accessory gland dysfunction. Very high volume can dilute sperm concentration. Ejaculate volume is part of the standard semen analysis and is combined with concentration to calculate total sperm count.
Sperm Vitality
Sperm vitality (or viability) is a measure of the proportion of live sperm in a semen sample, regardless of whether they are motile. It is assessed by staining (eosin-nigrosin or hypoosmotic swelling test). WHO 2021 reference: ≥54% live sperm. Vitality testing is particularly important when motility is very low — it distinguishes between immotile but living sperm (which can be used in ICSI) and necrospermia (high proportion of dead sperm). Live but immotile sperm can be identified and selected for ICSI using the hypoosmotic swelling test.
DNA Fragmentation
DNA fragmentation refers to single or double-strand breaks in the sperm DNA helix. It is measured as the DNA Fragmentation Index (DFI) and is distinct from standard semen analysis parameters. High DNA fragmentation impairs fertilisation, embryo development, implantation, and increases miscarriage risk — even when count, motility, and morphology are normal. It is a recommended test for unexplained infertility, recurrent IVF/ICSI failure, and recurrent pregnancy loss. Assays include TUNEL, SCSA, SCD, and comet assay.
DFI (DNA Fragmentation Index)
DFI (DNA Fragmentation Index) is a quantitative metric of sperm DNA damage, expressed as a percentage of sperm with fragmented DNA in a sample. DFI <15%: low fragmentation — favourable prognosis. DFI 15–25%: borderline — may affect outcomes. DFI >25%: high — significantly impairs IVF/ICSI outcomes and increases miscarriage risk. DFI is measured using SCSA, TUNEL, SCD, or comet assay. It is not detected by standard semen analysis and requires a separate dedicated test.
Day 3 FSH
Day 3 FSH is a blood test measuring follicle-stimulating hormone on the second or third day of the menstrual cycle. At this point in the cycle, FSH should be low — if the ovaries are healthy and responsive, they produce inhibin B and estradiol, which suppress FSH. A high Day 3 FSH (>10 IU/L) suggests that the pituitary gland is working harder than normal to recruit follicles, indicating diminished ovarian reserve. It was the primary ovarian reserve marker before AMH became widely available. Day 3 FSH is interpreted alongside Day 3 estradiol — a high estradiol can artificially normalise an elevated FSH reading.
Estradiol (E2)
Estradiol (E2) is the primary biologically active form of estrogen measured in fertility care. It is produced by granulosa cells of growing follicles and reflects follicular activity throughout the cycle. In baseline fertility testing, Day 3 estradiol is measured alongside FSH — an elevated baseline estradiol (>200 pmol/L) may suppress FSH, masking an elevated reading. During IVF stimulation, serial estradiol measurements are taken every 2–3 days to monitor follicle growth: each mature follicle contributes approximately 700–1,000 pmol/L. Very high estradiol during stimulation signals OHSS risk and may require cycle modification.
Serum Progesterone
Serum progesterone is a blood test measuring circulating progesterone levels. In fertility assessment, it is most commonly measured on Day 21 of a 28-day cycle (approximately 7 days after expected ovulation) to confirm that ovulation has occurred. A mid-luteal progesterone >25 nmol/L (>8 ng/mL) confirms ovulation. In IVF cycles, serum progesterone is also measured on trigger day — a premature rise (>1.5 ng/mL) on the day of trigger injection indicates early luteinisation, which impairs endometrial receptivity and warrants a freeze-all strategy rather than fresh transfer.
Prolactin
Prolactin is a pituitary hormone primarily responsible for milk production after childbirth. When elevated outside of pregnancy and breastfeeding (hyperprolactinaemia), it suppresses GnRH, FSH, and LH — causing irregular or absent ovulation, cycle disruption, and infertility. Common causes of elevated prolactin include pituitary adenoma (prolactinoma), hypothyroidism, antipsychotic medications, and stress. Prolactin testing is included in the standard female fertility hormone panel. Hyperprolactinaemia is highly treatable — dopamine agonists (cabergoline, bromocriptine) normalise levels and restore ovulation in most patients within weeks.
TSH (Thyroid-Stimulating Hormone)
TSH (thyroid-stimulating hormone) is secreted by the pituitary gland and regulates thyroid hormone production. In fertility medicine, TSH is routinely tested because thyroid dysfunction — both hypothyroidism and hyperthyroidism — can disrupt ovulation, menstrual cycle regularity, implantation, and pregnancy maintenance. The optimal TSH range for women trying to conceive and in early pregnancy is <2.5 mIU/L. Subclinical hypothyroidism (TSH 2.5–10) is associated with increased miscarriage risk and is treated with levothyroxine during fertility treatment. Testing is included in all preconception and infertility baseline panels.
Thyroid Function Tests
Thyroid function tests are a panel of blood tests assessing thyroid health — primarily TSH, and if indicated, free T3 (FT3) and free T4 (FT4). In fertility care, thyroid dysfunction is an important and often underdiagnosed cause of ovulatory dysfunction, irregular cycles, and recurrent miscarriage. Both hypothyroidism (low thyroid function, high TSH) and hyperthyroidism (overactive thyroid, low TSH) impair fertility. Subclinical hypothyroidism — where TSH is mildly elevated but T4 is normal — is treated with levothyroxine during fertility treatment. Thyroid function tests are part of the standard preconception and infertility workup for all women.
Testosterone
Testosterone is an androgen hormone measured in fertility evaluations for both sexes. In women, elevated testosterone is a hallmark of hyperandrogenism — the biochemical signature of PCOS — and can cause irregular cycles, anovulation, acne, and hirsutism. Total and free testosterone are both measured; free testosterone (the biologically active fraction) is a more sensitive marker of androgen excess. In men, low testosterone (hypogonadism) impairs spermatogenesis and libido. Normal female total testosterone: <2.5 nmol/L; male: 10–35 nmol/L. Testosterone is interpreted alongside DHEAS, SHBG, and LH:FSH ratio for a complete androgen profile.
DHEAS (Dehydroepiandrosterone Sulfate)
DHEAS (dehydroepiandrosterone sulfate) is an androgen produced primarily by the adrenal glands. It is measured in hyperandrogenism workups to distinguish adrenal from ovarian androgen excess. Elevated DHEAS suggests adrenal contribution to androgen excess — pointing toward non-classic congenital adrenal hyperplasia (NCAH) or adrenal tumours, rather than PCOS alone. DHEAS levels decline with age and are not affected by the menstrual cycle, making timing of testing flexible. In fertility medicine, DHEAS supplementation (at 25–75 mg/day) has been investigated as a means of improving ovarian response in poor responders undergoing IVF, though evidence remains mixed.
SHBG (Sex Hormone-Binding Globulin)
SHBG (sex hormone-binding globulin) is a protein produced by the liver that binds to sex hormones — particularly testosterone and estradiol — and regulates their bioavailability. Only the fraction of hormone not bound to SHBG (the free fraction) is biologically active. Low SHBG increases free androgen availability, worsening hyperandrogenism in PCOS. SHBG is suppressed by insulin resistance, obesity, and androgens themselves — and is raised by estrogen and thyroid hormone. In fertility assessment, SHBG is measured alongside testosterone to calculate free androgen index (FAI) and assess the degree of effective androgen excess.
Baseline Ultrasound
A baseline ultrasound is a transvaginal pelvic ultrasound performed early in the menstrual cycle (typically Day 2–3) before starting fertility treatment. It assesses antral follicle count (ovarian reserve), ovarian size, the presence of ovarian cysts, endometrial thickness, and uterine anatomy. A baseline ultrasound confirms that no residual cysts from the previous cycle are present before starting IVF stimulation — a large ovarian cyst may indicate the need to delay stimulation. In IVF cycles, baseline scans are the starting point for all subsequent monitoring.
Pelvic Ultrasound
A pelvic ultrasound is an imaging examination of the female reproductive organs — uterus, ovaries, and fallopian tube regions — using high-frequency sound waves. It is performed either transabdominally (via the abdomen, with a full bladder) or transvaginally (with a vaginal probe). Pelvic ultrasound is the primary imaging tool in fertility evaluation, used to diagnose fibroids, ovarian cysts, PCOS morphology, endometrial polyps, hydrosalpinx, and uterine abnormalities. In fertility treatment cycles, serial pelvic ultrasounds monitor follicle development and endometrial thickness.
Transvaginal Ultrasound (TVS)
Transvaginal ultrasound (TVS) is an ultrasound examination performed by inserting a thin probe into the vagina. Because the probe is closer to the pelvic organs, it provides significantly higher resolution imaging than transabdominal ultrasound — allowing accurate measurement of ovarian follicles (to the millimetre), endometrial thickness, and detection of small pathology such as polyps or early ectopic pregnancies. TVS does not require a full bladder and is well-tolerated. In IVF monitoring, TVS is performed repeatedly (every 1–3 days) during stimulation to track follicle growth and guide trigger timing.
Follicle Monitoring
Follicle monitoring is serial transvaginal ultrasound performed across a natural or stimulated cycle to track the growth of ovarian follicles and time interventions precisely. In natural and ovulation induction cycles, it confirms follicle maturity (dominant follicle ≥18 mm) and guides trigger shot timing or IUI scheduling. In IVF stimulation, monitoring scans are performed every 1–3 days from Day 5 onward, measuring follicle diameter and assessing estradiol rise. The trigger injection is given when lead follicles reach 17–20 mm and estradiol is appropriate for the follicle cohort.
Tubal Patency
Tubal patency refers to whether the fallopian tubes are open (patent) and functionally capable of transporting sperm toward the egg and the fertilised embryo toward the uterus. Blocked or damaged tubes — due to prior infection (PID), endometriosis, or surgery — are a significant cause of infertility. Tubal patency is assessed by HSG (hysterosalpingogram), HyCoSy (ultrasound with contrast), or laparoscopy with dye test. Blocked tubes are treated surgically (tuboplasty) or bypassed entirely using IVF, which does not require patent fallopian tubes.
Saline Sonogram (SIS)
A saline sonogram (saline infusion sonography, SIS) is a minimally invasive ultrasound procedure in which sterile saline solution is instilled into the uterine cavity through a thin catheter, then imaged by transvaginal ultrasound. The fluid distends the cavity, allowing detailed visualisation of the endometrial surface — detecting polyps, submucosal fibroids, uterine septum, and adhesions that are often invisible on standard ultrasound. SIS is a first-line uterine cavity evaluation tool before IVF, as intrauterine abnormalities significantly reduce implantation rates and are correctable before transfer.
SIS (Saline Infusion Sonography)
SIS stands for saline infusion sonography — the formal medical abbreviation for a saline sonogram. It is used interchangeably with "saline sonogram" and "sonohysterogram." SIS evaluates the uterine cavity using transvaginal ultrasound enhanced by saline instillation, providing detailed imaging of the endometrial lining. It is particularly useful for detecting intrauterine polyps and submucosal fibroids that would require hysteroscopic treatment before IVF. SIS is less invasive than hysteroscopy and does not require general anaesthesia, making it an accessible first-line cavity assessment tool.
Hysteroscopy
Hysteroscopy is a procedure in which a thin, lighted camera (hysteroscope) is passed through the cervix into the uterine cavity under direct visualisation. It is both a diagnostic tool (to identify polyps, fibroids, septa, adhesions) and a therapeutic tool — the same instrument can be used to remove polyps (polypectomy), divide septa (metroplasty), lyse adhesions (adhesiolysis), or remove submucosal fibroids. Hysteroscopy is the gold standard for uterine cavity evaluation before IVF. Office hysteroscopy (without anaesthesia) is increasingly available and well-tolerated. In India, diagnostic hysteroscopy costs ₹8,000–₹25,000; operative hysteroscopy costs ₹25,000–₹80,000.
Treatments
IVF (In Vitro Fertilisation)
IVF (In Vitro Fertilisation) is an assisted reproductive technology (ART) in which eggs are retrieved from the ovaries and fertilised with sperm outside the body in a controlled laboratory environment, and the resulting embryo is then transferred into the uterus to achieve pregnancy. IVF is used to help individuals or couples overcome fertility challenges such as blocked fallopian tubes, ovulation disorders, male factor infertility, or unexplained infertility, with the goal of increasing the chances of successful conception when natural methods or simpler treatments like IUI have not been effective.
IUI (Intrauterine Insemination)
IUI (Intrauterine Insemination) is a fertility treatment where washed, concentrated sperm is placed directly into the uterus through a thin catheter. This is done around the time of ovulation. It bypasses the cervix, putting sperm closer to the egg. IUI is used for mild male factor infertility, cervical mucus problems, ovulation disorders, or unexplained infertility. The aim is to increase the number of healthy sperm reaching the fallopian tubes.
ICSI (Intracytoplasmic Sperm Injection)
ICSI is an advanced fertility technique. A single healthy sperm is injected directly into the centre of a mature egg using a fine glass needle. The procedure is done under a high-powered microscope. ICSI is used for severe male factor infertility — very low count, poor motility, or abnormal morphology. It is also used when previous IVF cycles produced poor fertilisation results. Even with very low sperm quality, ICSI can still achieve fertilisation.
Ovulation Induction
Ovulation Induction is a fertility treatment that uses medications to stimulate the ovaries. Oral drugs like Letrozole or Clomiphene, or injectable hormones, are used. The goal is to trigger the development and release of one or more mature eggs. It is used for women with irregular or absent ovulation — including those with PCOS or hypothalamic amenorrhea. Treatment can support natural conception through timed intercourse, or be combined with IUI.
IVF with Donor Eggs
IVF with Donor Eggs is an assisted reproductive procedure in which eggs from a healthy, medically screened donor are fertilised with the partner's or donor sperm in a laboratory, and the resulting embryo is transferred into the recipient's uterus to achieve pregnancy. This treatment is used when a woman cannot produce viable eggs of her own due to diminished ovarian reserve, premature ovarian failure, advanced maternal age, or repeated IVF failure, with the goal of achieving pregnancy using high-quality donor eggs that significantly improve success rates.
Embryo Transfer
Embryo Transfer is the final step of the IVF process. A laboratory-cultured embryo is placed into the uterus through the cervix using a thin, flexible catheter guided by ultrasound. No anaesthesia is needed. The transfer can be a fresh transfer within the same IVF cycle, or a frozen embryo transfer (FET) in a later cycle. The goal is successful implantation and pregnancy.
Timed Intercourse
Timed intercourse is a first-line fertility strategy in which sexual intercourse is deliberately planned and scheduled to coincide with the fertile window — the 5–6 days leading up to and including ovulation. It is the least invasive fertility intervention and is typically recommended as an initial approach for couples with mild or unexplained infertility, or as an adjunct to ovulation induction medications. Timing is guided by LH urine tests (ovulation predictor kits), basal body temperature charting, or ultrasound follicle tracking. Intercourse is usually recommended every 1–2 days during the fertile window to maximise the likelihood of sperm meeting the released egg.
Minimal Stimulation IVF
Minimal stimulation IVF (mini-IVF) uses significantly lower doses of gonadotropins (75–150 IU/day) or oral medications (clomiphene/letrozole) than conventional IVF to retrieve 1–5 eggs per cycle. It reduces medication cost and OHSS risk. Targeted at poor ovarian responders, patients preferring fewer medications, or those with ethical reservations about creating large numbers of embryos. Multiple cycles may be needed to bank sufficient embryos.
Natural Cycle FET
Natural cycle FET is a frozen embryo transfer protocol in which the embryo is transferred in alignment with the patient's spontaneous ovulation cycle — without exogenous hormones for endometrial preparation. It relies on natural LH surge and endogenous progesterone. Embryo transfer occurs 5 days after confirmed ovulation (blastocyst) or 3 days after (cleavage embryo). Suitable only for women with regular ovulatory cycles. Evidence shows comparable outcomes to medicated FET in normal responders.
Medicated FET
Medicated FET is a frozen embryo transfer protocol using exogenous estrogen (tablets or patches) to grow the endometrium followed by exogenous progesterone to trigger secretory transformation. Transfer is scheduled 5 days after progesterone start (blastocyst) or 3 days after (cleavage embryo). Suitable for all patients including anovulatory and irregular-cycle women. Luteal phase support (estrogen + progesterone) continues until 10–12 weeks of pregnancy.
Endometrial Preparation
Endometrial preparation is the hormonal or natural-cycle process of conditioning the uterine lining to achieve implantation receptivity before embryo transfer. It targets a trilaminar endometrium ≥7mm thick. Methods include natural cycle (endogenous estrogen and LH surge), medicated cycle (exogenous estrogen + progesterone), and modified natural cycle (natural ovulation + hCG trigger). The window of implantation opens 5 days after progesterone exposure (for blastocysts).
OHSS Prevention
OHSS prevention encompasses the clinical strategies used to identify high-risk patients before IVF stimulation and modify the protocol to prevent ovarian hyperstimulation syndrome. Key strategies: low-dose stimulation start, close monitoring, GnRH agonist trigger (instead of hCG), freeze-all strategy, and dopamine agonist (cabergoline). Severe OHSS can be reduced to near zero with a comprehensive prevention protocol.
Dual Stimulation
Dual stimulation (DuoStim) is an advanced IVF strategy that performs two consecutive stimulation and egg retrieval cycles within a single menstrual cycle — one in the follicular phase and one in the luteal phase. It doubles egg yield per month in poor ovarian responders and oncofertility patients. All embryos from both retrievals are cryopreserved; transfer occurs in a subsequent cycle. Average total egg yield: 4–8 eggs per DuoStim cycle (vs 2–4 from two separate conventional cycles).
Natural Cycle IVF
Natural cycle IVF retrieves the single egg selected by the body's own hormonal cycle — without stimulation medications. The naturally dominant follicle is monitored, triggered at maturity, and retrieved for fertilisation via ICSI in the laboratory. No injections required. Suitable for poor ovarian responders, patients who cannot use hormonal medications, or those seeking the most medication-free IVF option. Live birth rate per retrieval: 5–15%.
What is Egg Freezing
Egg freezing (oocyte cryopreservation) is a fertility preservation procedure in which unfertilised eggs are retrieved after ovarian stimulation, vitrified (flash-frozen) at −196°C, and stored for future IVF use. Post-thaw egg survival rate: >90% with vitrification. Age-dependent success: best outcomes before age 35. Indications: social (elective), medical (pre-chemotherapy), oncofertility, and gender-affirming care.
What is Embryo Freezing
Embryo freezing (embryo cryopreservation) is the vitrification and cryostorage of fertilised eggs (embryos) at the cleavage or blastocyst stage at −196°C for future transfer. Post-thaw survival rate: >95% with vitrification. Embryos stored in this way can be transferred in future FET cycles, potentially years later. It is integral to modern IVF — used for surplus embryos, freeze-all strategies, PGT cycles, and fertility preservation.
Tests
AMH Test (Anti-Müllerian Hormone)
The AMH Test is a simple blood test that measures the level of Anti-Müllerian Hormone (AMH) in the bloodstream, a protein produced by the granulosa cells in the ovarian follicles that directly reflects a woman's ovarian reserve — the number of eggs remaining in her ovaries. The AMH test can be performed on any day of the menstrual cycle and is used to assess fertility potential, predict response to IVF stimulation, and guide treatment planning, with the goal of giving doctors and patients a reliable picture of reproductive capacity and helping determine the most appropriate fertility treatment approach.
HSG Test (Hysterosalpingography)
HSG (Hysterosalpingography) is a diagnostic X-ray procedure. A contrast dye is injected through the cervix into the uterus and fallopian tubes. X-ray images show whether the tubes are open or blocked. It also reveals the shape of the uterine cavity. Doctors use HSG to identify blocked tubes, polyps, fibroids, or a septate uterus that may be preventing pregnancy.
Semen Analysis
Semen Analysis is the main test for evaluating male fertility. A semen sample is examined under a microscope. The lab checks sperm count, motility (movement), morphology (shape), volume, and pH. It is one of the first tests done when a couple is having difficulty conceiving. Results can identify low sperm count, poor motility, or abnormal morphology. These findings guide the next steps — from lifestyle changes to IUI or ICSI.
Antral Follicle Count (AFC)
Antral Follicle Count (AFC) is a transvaginal ultrasound test. It is done early in the menstrual cycle — usually on Day 2 to 5. The doctor counts small resting follicles (2–10mm) on both ovaries. Each follicle represents a potential egg. AFC is used alongside the AMH blood test to assess ovarian reserve and predict how well the ovaries will respond to IVF stimulation.
Karyotyping
Karyotyping is a genetic test. A blood sample is taken and the chromosomes are stained, arranged, and examined under a microscope. The test looks for structural or numerical problems in a person's genetic makeup. In fertility medicine, it is used to investigate recurrent miscarriage, repeated IVF failure, or azoospermia. It can identify chromosomal disorders — such as translocations, Turner syndrome, or Klinefelter syndrome — that may be causing infertility.
SCSA (Sperm Chromatin Structure Assay)
SCSA (Sperm Chromatin Structure Assay) is a flow cytometry-based laboratory test that evaluates sperm DNA integrity by measuring the susceptibility of sperm chromatin to denaturation. It calculates the DNA Fragmentation Index (DFI) and High DNA Stainability (HDS) values. SCSA is one of the most validated and widely published methods for measuring sperm DNA damage. DFI >25% on SCSA is associated with significantly reduced fertility and increased miscarriage risk. It is used in the investigation of unexplained infertility, recurrent miscarriage, and repeated ART failure.
HSG (Hysterosalpingogram)
HSG (hysterosalpingogram) is a radiological test using X-ray fluoroscopy and contrast dye to examine the uterine cavity and assess fallopian tube patency. A thin catheter is passed through the cervix and contrast dye is injected — X-ray images show whether the dye spills freely through both tubes into the pelvis (patent) or stops at a blockage. HSG also outlines the uterine cavity, revealing polyps, fibroids, a septum, or adhesions. It is performed on Day 6–12 of the menstrual cycle. HSG is recommended for all women before IUI and as part of the infertility workup when tubal disease is suspected.
Hysterosalpingogram
Hysterosalpingogram is the full medical name for the HSG test — a fluoroscopic X-ray procedure using uterine contrast injection to assess tubal patency and uterine cavity anatomy. The term derives from the Greek: hystero (uterus) + salpingo (fallopian tube) + gram (image). Hysterosalpingogram is used to diagnose tubal blockage, hydrosalpinx, uterine anomalies, and intrauterine adhesions as part of the standard female infertility workup. It is commonly abbreviated to HSG in clinical practice. The test is performed in a radiology department or fertility clinic, takes 15–30 minutes, and does not require anaesthesia.
Conditions
PCOS (Polycystic Ovary Syndrome)
PCOS is a common hormonal disorder where the ovaries produce too many male hormones (androgens). This leads to irregular or absent periods, multiple small cysts on the ovaries, and symptoms like acne, weight gain, and excess hair. PCOS affects about 1 in 5 women of reproductive age in India. It is the most common cause of anovulatory infertility — where no egg is released. However, it is highly treatable through lifestyle changes, ovulation-inducing medications, IUI, or IVF.
Endometriosis
Endometriosis is a chronic condition. Tissue similar to the uterine lining grows outside the uterus. It most commonly affects the ovaries, fallopian tubes, and pelvic lining. This tissue responds to hormonal changes, causes inflammation, and forms scar tissue. Endometriosis can damage egg quality, block the fallopian tubes, and make embryo implantation difficult. Treatment includes laparoscopic surgery to remove the abnormal tissue. IVF may be needed to improve the chances of pregnancy.
Unexplained Infertility
Unexplained Infertility is diagnosed when a couple cannot conceive after 12 months of regular unprotected intercourse. All standard fertility tests come back normal. This includes semen analysis, ovulation assessment, HSG, and hormonal panels. No identifiable cause is found. It accounts for about 25–30% of all infertility cases. Treatment follows a stepwise approach: ovulation induction and timed intercourse first, then IUI, then IVF if needed.
Low Ovarian Reserve (Diminished Ovarian Reserve)
Low Ovarian Reserve means a woman has fewer eggs than expected for her age. It is measured by low AMH levels and a low Antral Follicle Count on ultrasound. It is most common in women over 35, but can also affect younger women due to genetic factors, autoimmune conditions, or prior ovarian surgery. Low reserve reduces the number of eggs available for IVF — but does not always affect egg quality in younger patients. Treatment includes modified IVF protocols or donor egg IVF.
Azoospermia
Azoospermia means there is no sperm in the ejaculate. It affects about 1% of all men and 10–15% of men with infertility. There are two types. In obstructive azoospermia, sperm is produced normally but a blockage stops it from coming out. In non-obstructive azoospermia, the testes do not produce enough sperm. Both types can be treated. Surgical sperm retrieval (TESA or MESA) is used to collect sperm. This is then combined with ICSI to achieve pregnancy.
Premature Ovarian Failure (POI)
Premature Ovarian Insufficiency (POI) is when the ovaries stop working normally before the age of 40. This causes irregular or absent periods, high FSH levels, very low AMH, and reduced oestrogen. POI affects about 1% of women. Causes include genetic factors, autoimmune disorders, or chemotherapy. Natural conception is rare but not impossible. The most effective fertility treatment is IVF with donor eggs, supported by hormone replacement therapy.
Recurrent Miscarriage
Recurrent Miscarriage means two or more pregnancy losses before 20 weeks. It affects about 1–2% of couples. Causes include chromosomal problems in the embryo, uterine structural issues (fibroids, polyps, or a septum), hormonal disorders, blood clotting disorders, and autoimmune conditions. A full diagnostic workup finds a treatable cause in 50–60% of cases. This workup includes karyotyping, hysteroscopy, hormonal tests, and thrombophilia screening. Treating the underlying cause significantly improves the chances of a future successful pregnancy.
Adenomyosis
Adenomyosis is a condition in which endometrial glands and stroma grow within the muscular wall of the uterus (myometrium), causing the uterus to enlarge, become boggy, and contract abnormally. It is associated with heavy, painful periods and may impair fertility by disrupting the uterine contractions needed for embryo implantation and sperm transport. In IVF, adenomyosis is associated with reduced implantation and pregnancy rates — particularly with severe or diffuse disease. It is diagnosed by transvaginal ultrasound or MRI. Treatment options include hormonal suppression (GnRH agonists) prior to IVF and, in selected cases, surgical treatment.
Fibroids (Uterine Leiomyomas)
Fibroids (uterine leiomyomas) are benign smooth-muscle tumours of the uterine wall — the most common benign tumour in women of reproductive age, affecting up to 70% of women by age 50. They are classified by location: submucosal (into the cavity — most fertility-impairing), intramural (within the wall), and subserosal (on the outer wall). Submucosal and large intramural fibroids distorting the uterine cavity are associated with reduced implantation and IVF success. Surgical removal (myomectomy) is indicated before IVF when the cavity is distorted. Fibroids are diagnosed by ultrasound, saline sonogram, or hysteroscopy.
Submucosal Fibroid
A submucosal fibroid is a uterine fibroid that projects into the uterine cavity. It is the fibroid type most strongly associated with reduced fertility and IVF failure — it physically distorts the endometrial surface, impairs embryo implantation, and increases miscarriage risk. Even small submucosal fibroids (<2 cm) reduce IVF success rates. They are classified by depth of intracavitary protrusion (FIGO type 0: entirely within cavity; type 1: >50% intracavitary; type 2: <50% intracavitary). Removal is recommended before IVF — primarily by operative hysteroscopy (hysteroscopic myomectomy).
Intramural Fibroid
An intramural fibroid is a uterine fibroid located within the muscular wall of the uterus, not projecting into the cavity. Small intramural fibroids (<3–4 cm) that do not distort the cavity have limited impact on fertility. Larger intramural fibroids (>4–5 cm) or those causing cavity distortion are associated with reduced implantation rates and may warrant myomectomy before IVF. The decision to operate is individualised — risks of myomectomy (uterine scarring, weakened wall) must be weighed against the potential fertility benefit. Intramural fibroids are the most common fibroid type.
Endometrial Polyp
An endometrial polyp is a benign overgrowth of the endometrial lining — a stalk of glands, stroma, and blood vessels protruding into the uterine cavity. Polyps are common (found in 10–35% of infertile women) and are a recognised cause of abnormal uterine bleeding and reduced implantation. Even small polyps (<1 cm) in the vicinity of the embryo transfer site may impair IVF success. They are detected by transvaginal ultrasound, saline sonogram, or hysteroscopy. Removal by hysteroscopic polypectomy before IVF transfer is standard practice — associated with significantly improved pregnancy rates.
Hydrosalpinx
A hydrosalpinx is a chronically blocked, fluid-filled fallopian tube — typically caused by previous pelvic infection (PID), chlamydia, endometriosis, or prior surgery. The fluid that accumulates inside the blocked tube is toxic to embryos and, when it refluxes into the uterine cavity, dramatically reduces IVF success — by approximately 50%. Hydrosalpinx is diagnosed by transvaginal ultrasound or HSG. Before IVF, treatment is strongly recommended: laparoscopic salpingectomy (tube removal) or, alternatively, proximal tubal occlusion. After salpingectomy, IVF live birth rates return to those expected for the patient's age and diagnosis.
Tubal Factor Infertility
Tubal factor infertility refers to infertility caused by blocked, damaged, or absent fallopian tubes, preventing the sperm and egg from meeting or the embryo from reaching the uterus. It accounts for approximately 25–35% of female infertility causes. Common causes include pelvic inflammatory disease (PID), Chlamydia trachomatis infection, endometriosis, previous ectopic pregnancy, and prior pelvic surgery. Diagnosis is by HSG or laparoscopy. Treatment depends on severity: mild proximal blockage may be treated surgically (salpingostomy, cornual catheterisation); hydrosalpinx requires salpingectomy; and all tubal factor patients benefit from IVF, which bypasses the tubes entirely.
Salpingitis Isthmica Nodosa (SIN)
Salpingitis isthmica nodosa (SIN) is a condition characterised by nodular thickening of the fallopian tube at its isthmic (narrowest) segment — caused by diverticula (pouches) of tubal epithelium extending into the muscle wall. It is associated with tubal obstruction, infertility, and significantly elevated risk of ectopic pregnancy. SIN is most commonly detected on HSG as characteristic spikelike projections from the cornual region. It is more common in women with a history of pelvic infection. Because SIN carries a very high ectopic pregnancy risk in the event of natural conception, IVF (which bypasses the tubes) is the recommended treatment.
Asherman Syndrome
Asherman syndrome (intrauterine adhesions or synechiae) is a condition in which bands of scar tissue form inside the uterine cavity, following uterine trauma — most commonly after dilation and curettage (D&C), postpartum haemorrhage management, or uterine surgery. Adhesions can be mild (fine filmy bands) to severe (obliteration of the cavity). They cause menstrual abnormalities, recurrent miscarriage, implantation failure, and in severe cases, amenorrhoea. Diagnosis is by hysteroscopy (gold standard) or saline sonogram. Treatment is hysteroscopic adhesiolysis (surgical division of adhesions) under direct vision, followed by hormonal support to regenerate the endometrium.
Age-Related Fertility Decline
Age-related fertility decline is the progressive reduction in reproductive potential that occurs with advancing age in both sexes, most profoundly in women. Female fertility peaks in the early 20s, begins declining meaningfully from age 32, accelerates steeply after 37, and falls sharply after 40. The primary mechanism is oocyte aging — fixed oocyte supply combined with rising chromosomal aneuploidy rates as eggs age. By 40, over 60% of eggs are chromosomally abnormal; by 43, over 80%. This drives reduced conception rates, higher miscarriage rates, and lower IVF success per retrieved egg regardless of stimulation outcome.
Adhesions (Pelvic/Intrauterine)
Adhesions are abnormal fibrous bands of scar tissue that form between organs or tissue surfaces following inflammation, infection, surgery, or endometriosis. In fertility medicine, two types are clinically important: pelvic adhesions (between pelvic organs — ovaries, tubes, uterus, bowel — causing tubal damage and obstruction) and intrauterine adhesions (synechiae inside the uterine cavity — as in Asherman syndrome). Pelvic adhesions are diagnosed at laparoscopy; intrauterine adhesions by hysteroscopy or saline sonogram. Treatment is surgical lysis (adhesiolysis) — laparoscopic for pelvic adhesions, hysteroscopic for intrauterine. Severity ranges from thin filmy bands (easily divided) to dense fibrous adhesions (requiring careful sharp dissection).
OHSS
OHSS (ovarian hyperstimulation syndrome) is a complication of IVF ovarian stimulation in which the ovaries respond excessively to gonadotropin medications, causing them to enlarge and leak fluid into the abdomen and chest. Severity ranges from mild discomfort to a life-threatening condition requiring hospitalisation. Incidence: mild ~30%, severe ~0.5–2%. Risk is highest in PCOS patients, high responders (AMH >3.0 ng/mL, AFC >20), and donor egg cycles.
Ovarian Hyperstimulation Syndrome
Ovarian hyperstimulation syndrome (OHSS) is the full clinical name for the most serious acute complication of controlled ovarian stimulation. It results from excessive ovarian response to gonadotropins, triggering VEGF-mediated vascular permeability changes causing fluid to shift from blood vessels into the abdomen and chest. Graded mild, moderate, severe, and critical. Severe OHSS (0.5–2% of cycles) requires hospitalisation and carries DVT, renal failure, and ARDS risk.
What is Implantation Failure
Implantation failure occurs when a transferred embryo fails to attach to the uterine lining, resulting in a failed IVF cycle. It is the most common cause of IVF cycle failure. Causes include embryo chromosomal abnormality (50–60% of cases), endometrial factors (thin lining, displaced window of implantation), uterine abnormalities (polyps, fibroids, adhesions), and immunological factors (NK cell hyperactivity, thrombophilia).
Recurrent Implantation Failure
Recurrent implantation failure (RIF) is the repeated absence of implantation after multiple good-quality embryo transfers — defined as failure of ≥3 good-quality embryo transfers or ≥2 blastocyst transfers. RIF is distinct from recurrent miscarriage. Investigation protocol: PGT-A, ERA test, hysteroscopy, chronic endometritis biopsy, thrombophilia screen, and immunological assessment. Systematic workup significantly improves subsequent transfer outcomes.
Fertilization Failure
Fertilisation failure is the complete or near-complete absence of fertilisation of mature oocytes during an IVF or ICSI cycle. Defined as 0% or <25% fertilisation rate across all mature eggs retrieved. In conventional IVF, failure typically reflects a sperm-oocyte interaction defect; in ICSI, oocyte activation failure (PLCζ deficiency in sperm) is the primary cause. Assisted oocyte activation (AOA) restores fertilisation in 60–80% of PLCζ-deficient ICSI failure cases.
What is PCOS
PCOS (polycystic ovary syndrome) is the most common hormonal disorder in women of reproductive age, affecting 8–13% of women globally. It causes irregular or absent ovulation, elevated androgens (hyperandrogenism), and polycystic ovaries — and is the single most common cause of anovulatory infertility. Diagnosis requires 2 of 3 Rotterdam criteria. Treatment: letrozole (first-line ovulation induction), metformin, lifestyle modification, and IVF in non-responders.
What is Endometriosis
Endometriosis is a chronic inflammatory condition in which endometrium-like tissue grows outside the uterus — on the ovaries, fallopian tubes, peritoneum, and other structures. Affects ~10% of reproductive-age women. Causes pelvic pain, dysmenorrhoea, and infertility (30–50% of affected women). Three forms: peritoneal, endometrioma, and deep infiltrating endometriosis (DIE). Diagnosed by laparoscopy. Staged I–IV (ASRM).
What is Azoospermia
Azoospermia is the complete absence of sperm in the ejaculate, confirmed on two separate centrifuged semen analyses. Affects ~1% of all men and 10–15% of infertile men. Two types: obstructive azoospermia (OA — sperm produced but blocked) and non-obstructive azoospermia (NOA — impaired sperm production). Both treated with surgical sperm retrieval (TESE/Micro-TESE/PESA) combined with ICSI — enabling biological fatherhood.
What is Sperm Morphology
Sperm morphology is the assessment of sperm shape and structure on semen analysis, evaluated using strict Kruger (Tygerberg) criteria and reported as the percentage of normal-form sperm. Normal threshold: ≥4% normal forms (WHO 2021). Below 4% = teratozoospermia. Severe teratozoospermia (<1%) is associated with poor IVF fertilisation — ICSI is recommended. Globozoospermia (0% acrosome) requires ICSI + AOA.
What is DNA Fragmentation in Sperm
Sperm DNA fragmentation refers to breaks in the DNA strands within the sperm nucleus — measured as DNA fragmentation index (DFI). High DFI (>25%) significantly impairs fertilisation, embryo development, implantation, and live birth rates, and contributes to recurrent miscarriage. Not detected by standard semen analysis. Tested by SCSA, TUNEL, SCD (Halosperm), or Comet assay. Treatment: antioxidants, varicocelectomy, or testicular sperm (TESE) for very high DFI.
Procedures
Egg Retrieval (Oocyte Pick-Up)
Egg Retrieval (also called Oocyte Pick-Up or OPU) is a minor surgical procedure performed during IVF. Mature eggs are collected from the ovarian follicles using a thin needle guided by transvaginal ultrasound. The patient is under light sedation or anaesthesia throughout. The procedure takes about 20–30 minutes. It typically yields 8–15 eggs depending on the woman's age, ovarian reserve, and stimulation response. Retrieved eggs are then fertilised in the laboratory.
Embryo Freezing (Cryopreservation)
Embryo Freezing (Cryopreservation) is a laboratory procedure in which high-quality embryos produced during an IVF cycle are preserved at -196°C using a rapid freezing technique called vitrification, which prevents ice crystal formation and achieves post-thaw survival rates above 95%. Embryo freezing is used when surplus embryos are available after a fresh transfer, when a fresh transfer is not medically advisable, or when embryos are being stored for future family planning, with the goal of preserving viable embryos for later use in frozen embryo transfer (FET) cycles without the need for repeated ovarian stimulation and egg retrieval.
Laparoscopy (Keyhole Surgery)
Laparoscopy is a minimally invasive surgery, also called keyhole surgery. A thin camera (laparoscope) and small instruments are inserted through tiny incisions in the abdomen. The surgeon can directly view and treat the pelvic organs. It is used for endometriosis, ovarian cysts, fibroids, pelvic adhesions, and blocked fallopian tubes. Laparoscopy is both a diagnostic tool and a treatment. The goal is to improve natural conception rates or prepare the body for IVF.
Hysteroscopy
Hysteroscopy is a procedure used to examine the inside of the uterus. A thin, lighted camera called a hysteroscope is inserted through the cervix. The doctor views the uterine cavity on a monitor. Abnormalities such as polyps, fibroids, adhesions, or a uterine septum can be found and treated in the same session. Hysteroscopy is common in women with unexplained infertility or recurrent miscarriage. It is also done before IVF to ensure the uterine environment is ready for embryo implantation.
TESA / MESA (Surgical Sperm Retrieval)
TESA and MESA are surgical procedures used to retrieve sperm directly from the male reproductive tract. They are used when no sperm is present in the ejaculate. In TESA, a fine needle is inserted into the testis to extract sperm-containing tissue. In MESA, sperm is taken from the epididymis under a microscope — giving a higher yield and better quality. Both procedures are used for men with azoospermia, ejaculatory dysfunction, or failed vasectomy reversal. Retrieved sperm is used with ICSI to achieve fertilisation.
Polypectomy
Polypectomy is the surgical removal of a uterine polyp. In fertility medicine, it is performed hysteroscopically — the hysteroscope is inserted through the cervix and the polyp is removed under direct vision using a resectoscope or mechanical device. No incisions are required. Office polypectomy without general anaesthesia is increasingly used for small polyps. Polypectomy is indicated for all intrauterine polyps before IVF embryo transfer, before IUI, or in women with unexplained infertility or recurrent miscarriage. Evidence shows significant improvement in pregnancy rates after polypectomy.
Hormones
FSH (Follicle-Stimulating Hormone)
FSH (Follicle-Stimulating Hormone) is produced by the pituitary gland. In women, it stimulates the growth and maturation of ovarian follicles — each containing an egg. In men, it drives sperm production. Doctors measure FSH through a blood test on Day 2–3 of the menstrual cycle. High FSH suggests diminished ovarian reserve. Very low FSH may point to a hypothalamic or pituitary problem. FSH is a key part of any fertility hormone workup.
LH (Luteinizing Hormone)
LH (Luteinizing Hormone) is produced by the pituitary gland. It triggers ovulation — the release of a mature egg from the ovary. This happens through a rapid surge in LH levels, about 24–36 hours before the egg is released. LH can be measured by a blood test or detected at home with an ovulation predictor kit. Doctors use LH to time intercourse or IUI, diagnose ovulation disorders, and identify hormonal imbalances like PCOS — where LH is often chronically elevated.
Estrogen (Estradiol)
Estrogen (specifically Estradiol or E2) is the primary female reproductive hormone. It is produced by the developing ovarian follicles. Estrogen stimulates the growth of the uterine lining and supports follicle maturation. During IVF, estradiol levels are monitored through blood tests to track how the ovaries are responding to stimulation. Rising levels signal that follicles are growing. Doctors use this to time the trigger injection and egg retrieval at the right moment.
Progesterone
Progesterone is a hormone produced by the corpus luteum — the structure left in the ovary after ovulation. It prepares and maintains the uterine lining for embryo implantation. It also helps sustain early pregnancy. In IVF, progesterone supplementation is given during the luteal phase and early weeks of pregnancy. It can be taken as vaginal pessaries, oral tablets, or injections. The goal is to keep the uterine lining thick and receptive so the embryo can implant successfully.
AMH (Anti-Müllerian Hormone)
AMH (Anti-Müllerian Hormone) is a protein hormone produced by small follicles in the ovaries. It is a direct measure of a woman's ovarian reserve — how many eggs she has remaining. Unlike FSH and LH, AMH levels stay stable throughout the menstrual cycle. This means the test can be done on any day. Fertility specialists use AMH to assess reproductive potential, predict IVF response, and diagnose conditions such as PCOS (where AMH is often elevated).
Male Fertility
Low Sperm Count (Oligospermia)
Low Sperm Count (Oligospermia) means fewer than 15 million sperm per millilitre of semen. This reduces the chance of a sperm reaching and fertilising the egg. Causes include varicocele, hormonal imbalances, infections, genetic factors, heat exposure, smoking, alcohol, or obesity. Diagnosis is made with a semen analysis. Mild cases may respond to lifestyle changes and supplements. Moderate to severe cases are treated with IUI or ICSI.
Varicocele
Varicocele is an enlargement of the veins within the scrotum — similar to varicose veins in the legs. These enlarged veins raise the temperature inside the testicles. Higher temperature impairs sperm production, quality, and DNA integrity. Varicoceles affect about 15% of all men and up to 40% of infertile men. Diagnosis is done by physical examination and scrotal Doppler ultrasound. Surgical repair (varicocelectomy) improves sperm parameters in 60–70% of cases.
Sperm DNA Fragmentation
Sperm DNA Fragmentation means the DNA inside sperm cells has breaks or damage. Standard semen analysis does not detect this. High fragmentation is linked to lower natural conception rates and poorer IVF and ICSI outcomes. It is also linked to impaired embryo development and higher miscarriage risk. This can happen even when count, motility, and morphology appear normal. Testing is recommended for unexplained infertility, recurrent IVF failure, or recurrent miscarriage. Treatment includes antioxidant therapy, lifestyle changes, and advanced sperm selection during ICSI.
Erectile Dysfunction & Fertility
Erectile Dysfunction (ED) means a man cannot achieve or maintain an erection firm enough for intercourse. ED does not directly damage sperm quality. But it prevents natural conception by making vaginal intercourse difficult or impossible. Causes include vascular problems, neurological conditions, hormonal imbalances, medications, or lifestyle factors like smoking and obesity. Treatment options include oral medications (such as sildenafil), lifestyle changes, and counselling. IUI is also an option — it allows conception without intercourse by using a collected semen sample.
Micro-TESE
Micro-TESE (microsurgical testicular sperm extraction) is a surgical procedure performed under an operating microscope to retrieve sperm directly from seminiferous tubules in men with non-obstructive azoospermia. It identifies dilated, sperm-producing tubules with 6–25x magnification and achieves sperm retrieval in 30–60% of NOA cases — higher than conventional TESE. Retrieved sperm are used exclusively with ICSI.
PESA
PESA (percutaneous epididymal sperm aspiration) is a minimally invasive sperm retrieval procedure for obstructive azoospermia. A fine needle is inserted through the scrotal skin into the epididymis to aspirate sperm without surgical incision. Sperm retrieval rate is 80–100% in obstructive azoospermia. Retrieved sperm are used with ICSI. PESA is simpler and less costly than MESA but yields fewer and lower-quality sperm.
MESA
MESA (microsurgical epididymal sperm aspiration) is a surgical sperm retrieval technique that uses an operating microscope to aspirate sperm from individual epididymal tubules. It is used in obstructive azoospermia and yields larger quantities of higher-quality sperm than PESA. A single MESA can yield enough sperm for 3–5 future ICSI cycles with cryopreservation. Retrieved sperm achieve 70–80% fertilisation rates with ICSI.
TESE
TESE (testicular sperm extraction) is a surgical procedure that retrieves sperm directly from testicular tissue via biopsy. Used in both obstructive and non-obstructive azoospermia. Conventional TESE uses random blind biopsies (sperm retrieval: 80–100% in OA; 30–50% in NOA). Micro-TESE uses operating microscope magnification to identify productive tubules (higher retrieval in NOA). Retrieved sperm are used exclusively with ICSI.
Lifestyle & Supplements
Folic Acid
Folic acid is the synthetic form of folate (vitamin B9), recommended at 400–800 mcg/day starting at least one month before conception and continuing through the first trimester. It is the most evidence-based preconception supplement — reducing neural tube defect (NTD) risk by up to 70%. Higher doses (5 mg/day) are prescribed for women with prior NTD pregnancies, diabetes, or epilepsy. Folate is essential for DNA synthesis and cell division during early embryonic development.
Fertility Supplements
Fertility supplements are non-prescription products taken to support reproductive health. Evidence varies widely by supplement — folic acid and vitamin D have strong clinical support; CoQ10, omega-3, and zinc have moderate evidence for specific indications; most branded "fertility blends" lack robust clinical trial data. Supplements should complement, not replace, medical evaluation. Self-prescribing without diagnosis may delay appropriate treatment.
CoQ10 (Coenzyme Q10)
Coenzyme Q10 (CoQ10) is a fat-soluble antioxidant produced naturally in cells, essential for mitochondrial energy production (ATP synthesis). In fertility, CoQ10 is most studied for improving egg quality in women with diminished ovarian reserve and for improving sperm motility in men with asthenospermia. Typical doses used in fertility research: 400–600 mg/day (women); 200–300 mg/day (men). Evidence is promising but not definitive — no large RCTs confirm IVF success rate improvement.
Vitamin D
Vitamin D is a fat-soluble hormone-like vitamin synthesised in skin exposed to UVB light and obtained from diet and supplements. Vitamin D deficiency is highly prevalent in India (60–80% of reproductive-age adults) and is associated with PCOS, impaired ovarian function, reduced IVF implantation rates, and male factor infertility. Target serum level before fertility treatment: 40–60 ng/mL (100–150 nmol/L). Supplementation: 1,000–4,000 IU/day depending on baseline level; tested by serum 25(OH)D assay.
Antioxidants (Fertility)
Antioxidants are compounds that neutralise reactive oxygen species (ROS), reducing oxidative stress. In fertility, oxidative stress damages sperm DNA, impairs oocyte mitochondrial function, and disrupts embryo development. Key antioxidants studied in fertility: CoQ10, vitamin C (ascorbic acid), vitamin E (tocopherol), N-acetyl cysteine (NAC), selenium, zinc, and lycopene. Male antioxidant supplementation has the strongest evidence base — a Cochrane review found antioxidants may improve sperm motility and live birth rates in male factor infertility. Female evidence is more limited.
Male Fertility Supplements
Male fertility supplements are non-prescription products used to improve sperm quality by reducing oxidative stress, supporting mitochondrial function, and improving sperm DNA integrity. The strongest evidence exists for antioxidant combinations (vitamin C + E + selenium + zinc) and CoQ10 — a Cochrane review (2023) found antioxidants may improve sperm motility, count, and live birth rates in men with idiopathic male infertility. Lycopene improves morphology; L-carnitine supports sperm energy metabolism. Supplementation should be continued for at least 3 months (one full spermatogenesis cycle). Supplements do not replace investigation — sperm DNA fragmentation testing guides their targeted use.
Prenatal Vitamins
Prenatal vitamins are multivitamin formulations specifically designed for use before conception and during pregnancy, providing key micronutrients to support reproductive function and fetal development. Core components: folic acid (400–800 mcg, or 5 mg high-dose), iron, calcium, vitamin D, iodine, DHA (omega-3), and B12. Prenatal vitamins are not a substitute for a balanced diet — they are a nutritional safety net. Quality and dosing vary significantly between brands; evidence-based components should be verified before purchase.
Sleep (Fertility)
Sleep is a foundational biological process essential for hormonal regulation, immune function, and metabolic health — all of which directly affect reproductive potential. Chronic sleep disruption (under 7 hours per night or irregular circadian timing) is associated with disrupted LH and FSH pulsatility, reduced progesterone, impaired sperm parameters, and poorer IVF outcomes. Night shift work and circadian misalignment are specific fertility risk factors — they suppress melatonin, an antioxidant that protects oocytes and sperm during maturation.
Stress (Fertility)
Psychological stress activates the hypothalamic-pituitary-adrenal (HPA) axis, elevating cortisol and CRH — which can suppress GnRH pulsatility, disrupt LH and FSH secretion, impair ovulation, and reduce sperm quality. Severe acute stress can suppress ovulation in any given cycle. Chronic stress impairs treatment adherence, worsens treatment experience, and may modestly reduce IVF outcomes — though the relationship is complex and not fully established. Importantly, stress is not a substitute explanation for unexplained infertility. Addressing stress is valuable for quality of life regardless of its direct fertility impact.
Stress Reduction
Stress reduction in fertility care encompasses structured behavioural interventions used to lower psychological burden, improve coping, and support wellbeing during infertility investigation and treatment. Evidence-based approaches: mindfulness-based stress reduction (MBSR), cognitive behavioural therapy (CBT), yoga, acupuncture (limited evidence), and mind-body programmes (Domar). Stress reduction does not reliably improve IVF success rates as a standalone intervention — but it meaningfully improves anxiety, depression, and treatment adherence, reducing cycle dropout rates.
Mindfulness
Mindfulness is a contemplative practice involving intentional, non-judgmental attention to present-moment experience. In fertility care, mindfulness-based interventions (MBI) — particularly MBSR (mindfulness-based stress reduction) — are used to reduce infertility-related anxiety, depression, and emotional exhaustion. RCTs show that MBSR significantly reduces anxiety and depression in infertility patients. Some studies suggest improved IVF pregnancy rates in mindfulness programme participants — but evidence is not yet conclusive. Mindfulness is best understood as a quality-of-life intervention, not a fertility treatment.
Mental Health (Fertility)
Mental health in the fertility context refers to the psychological wellbeing of individuals and couples navigating infertility diagnosis, treatment, pregnancy loss, and complex reproductive decisions. Infertility is a significant psychological stressor — depression affects 35–40% of patients in active treatment, anxiety 40–50%. Mental health impacts treatment adherence, relationship quality, and clinical outcomes. Comprehensive fertility care integrates psychological support as standard — not optional — through access to therapy, fertility counselling, peer support groups, and mindfulness resources.
🏥 Find Fertility Clinics in Your City
Ready to take the next step? Connect with verified fertility specialists near you.